# The single solution

for parenteral nutrition


## **Aminoplex 5**


1 litre three times per day provides 15g. of utilisable nitrogen and 3000K calories; the nutrient content being derived from synthetic L-Form amino acids, sorbitol and alcohol.

## **Geistlich**Chester

In co-operation with Salvia-Werk G.m.b.H., Homburg/Saar, W. Germany.

Medical literature available from: Geistlich Sons Ltd., Newton Bank, Long Lane, Chester CH2 3QZ. Telephone Chester 47534-7





# Endoscopy confirms that De-Nol heals ulcers

Double-blind clinical trials, involving endoscopic diagnosis, follow-up and assessment, have shown De-Nol to heal up to 90% of gastric and duodenal ulcers, with safety; no serious side-effects being reported.

De-Nol \* heals gastric and duodenal ulcers

\* early relief of pain

\* is free from serious side-effects

"The combination of lack of side-effects in addition to promotion of ulcer healing suggests that (De-NoI) has a clinical role in the management of the ambulant patient with duodenal ulcer." GUT 1974 15 189-193.


"The degree of healing with (De-NoI) is comparable to, or better than that achieved by the most extensively used ulcer-healing agent, carbenoxolone sodium." BSG, Birmingham, September 1974; GUT 1974 15 833.

**De-Nol** 

tri-potassium di-citrato dismutnate

Unique ulcer therapy





For further information, contact:
Brocades (G.B.) Ltd.,
West Byfleet, Surrey.
Byfleet 45536.



"I Bring Peace"-73

#### "It is concluded that maintenance treatment of ulcerative colitis with sulphasalazine (salazopyrin) should be continued indefinitely unless contraindicated by side effects".1

The results of the above controlled trial carried out at the Nuffield Department of Clinical Medicine, Radcliffe Infirmary, Oxford are all the more welcome as earlier trials of cortisone<sup>2</sup> and prednisone<sup>3</sup> at standard dosages have shown them to be ineffective in reducing the number of recurrences of ulcerative colitis.

"Fortunately, Sulphasalazine tablets, 0.5 grams 4 times a day will prevent relapses in the majority of patients


with colitis, and only a few patients cannot tolerate this relatively small dose, which can be continued indefinitely since we do not know when, if ever, it can be safely stopped".4

Salazopyrin (sulphasalazine) is available as the plain 0.5g. tablet, o.5g. EN-tab and as an o.5g. suppository. Literature and detailed information on Salazopyrin are available on request.

Salazopyrin is a registered trade mark.

- to be continued indefinitely

Further information on request from:-Pharmacia (Great Britain) Ltd. Paramount House 75 Uxbridge Road, London W5 5SS. Telephone: 01-579 0102/7



"The patients who received dummy tablets had more than four times the relapse rate of those receiving sulphasalazine".1 (Salazopyrin). Both groups of patients had been satisfactorily maintained for 1-5 years on Salazopyrin prior to the study, in which they took Salazopyrin or placebo for 6 months.

References

Reterences 1. Gut (1973) 14 923 - 926 2. Brit. med. J. (1959) 1 387 - 394 3. Lancet (1965) 1 188 - 189 4. General Practitioner (1972) April 7 p.11



# fybogel

# the new therapeutic solution for the treatment of pressure diseases of the large bowel

DIVERTICULAR DISEASE IRRITABLE/SPASTIC COLON HAEMORRHOIDS ANAL FISSURE

These are the pression diseases of the large a wel—a wide range of conditions with a common aetiol factor: low level of file in the diet.

#### The pressure problem

Raised intra-colonic pressure due to excessive segmentation. This leads to the formation of diverticula when pressure builds up in an occluded segment.

Raised intra-abdominal pressure due to straining to evacuate the resulting concentrated stools. This may lead to the formation of haemorrhoids when pressure on the pelvic diaphragm occludes the venous return from the haemorrhoidal plexus.

#### Fybogel — the natural solution

By providing a natural fibre regimen Fybogel treats the main cause of pressure diseases—a low level of dietary fibre. Fybogel is a controlled regimen, presented as granules in single dose sachets. The granules disperse in water to make a palatable drink.




Full information is available on request from:


Reckitt & Colman Pharmaceutical Division, Hull HU8 7DS.

Each sachet contains 3.5g Ispaghula Husk BPC in an effervescent base.










# How much Caved-S can an intractable duodenal ulcer patient take?



For a full year without relapse, 12 tablets a day for up to 16 weeks\*

#### The Practitioner

June 1973 Vol. **210** pp. 820 ~ 823

\* This dosage regimen was established in a recent trial of Caved-S on patients all with intractable duodenal ulcer and a history of more than six relapses in the year prior to the trial. Of twenty patients receiving 12 Caved-S tablets a day for 16 weeks, 12 had no relapse in a full year's follow-up, and the other 8 had two or one relapse in the follow-up year. All these patients had actually been referred for surgery, but surgery was avoided in all cases. Another similar group of 20 patients received 8 Caved-S tablets a day for 8 weeks – the condition of patients selected was too serious for controls with a placebo. Of this second group 3 had no relapse, 7 up to two relapses, and 10 up to 4 relapses in a year's follow-up.

No significant side effects occurred. Only one patient discontinued treatment, and he later resumed treatment successfully. The authors conclude:

"Caved-S... should be given in high dosage before surgery is attempted in patients with duodenal ulcer who fail to respond to a low dose or other treatments."

**Caved-S** 

the ulcer fighter

Licence No. 0425/5000
Composition: Liquorice (not more than 3% glycrntizinic acid) 380 mg. bismuth subnitrate 100 mg. alum. hydrox gel 100 mg., light mag. carb. 200 mg., sod. bicarb. 100 mg., frangula bark 30 mg.; brown tab,

Tillotts Laboratories, 44 Lupus Street, London SW1V 3EB



Caved-S effective and economic in high dosage

# ACM endoscopes leave nothing to the imagination

Most surgeons today recognise the superiority of endoscopy as a means of confirming diagnoses of colon diseases. It can be quicker and easier than laparotomy, and is also less traumatic for patients and makes fewer demands on hospital facilities.

The premier instrument for colonic investigations is the ACM F9L coloscope. Advanced features include 12X magnification and a sharp, wide angle circular image three times larger than competitive instrument's.

With it a surgeon can clearly view as far as the caecum, take biopsy specimens and perform polypectomies. After surprisingly little practice, coloscopy can be most rewarding. And the ACM coloscope is exceptionally easy to use — a single, one-handed joystick controls the poly-directional tip.

There's a shorter version, too, the F9S which will reach to the transverse colon and beyond. For the experienced coloscopist there's

the dual channel F9A, a major operative, as well as diagnostic instrument. To find out more, please use the coupon. Or write or telephone.

Please tell me more about ACM endoscopes.  I would like literature only	
Please arrange a visit My telephone number is	
Name	
Address	
	(G/4/75)


#### ACM Endoscopes - clearly the best


(ACM)

Wappler Endoscopy Limited,
Park House, 22 Park Street, Croydon, Surrey, CRO OYH
Telephone: 01-686 4241

WAPPLER Endoscopy Limited

ACM endoscopes for gastro-enterology, bronchoscopy, urology, gynaecology and teaching.





Bartop 100 gives the quality and accuracy expected of Double Contrast X Rays.

"...Small gastric carcinomas of the order of 2-3 cm can be demonstrated, benign and malignant disease can be distinguished and the surface changes in such conditions as chronic erosive gastritis and Menetriere's disease can be visualised as well as the small 'ulcers' following endoscopic biopsies".

KREEL et al, Clin, Radiol. (1973) 24 307.

# Baritop 100


Baritop 100 is an elegant, palatable radiological barium suspension at 100% w/v in convenient 300 ml. cans.\*Baritop Effervescent tablets for use with Baritop 100 are available.

Full information is available on request from:



Concept Pharmaceuticals Ltd. Rickmansworth WD3 1EZ

\*Bariton is a registered trade ma



heartburn and disturbed sleep.

By protecting the oesophageal mucosa from reflux attack Gaviscon relieves night-time heartburn as no other preparation can.

In a recent trial\* intraoesophageal pH traces recorded over a continuous fifteen hour period, including the hours of sleep, showed:

"... that both the number of reflux episodes and the percentage time during which intraoesophageal pH is in the acid range are significantly reduced by Gaviscon but not by antacids or by placebo".

Which means goodnight to heartburn!

Gaviscon contains: Alginic Acid B.P.C., Sodium Alginate B.P.C., Magnesium Trisilicate B.P., Dried Aluminium Hydroxide Gel B.P., Sodium Bicarbonate B.P., Sucrose B.P. and Mannitol B.P. Gaviscon is available as mint-flavoured tablets and chocolate-flavoured granules.

\*Lancet (1974), i, 109, Fig. continuous recording of lower oesophageal pH before and after treatment with Gaviscon. Further information is available on request from: RECKITT & COLMAN PHARMACEUTICAL DIVISION, HULL HU8 7DS.

### Histocompatibility and Rheumatic Disease

The Proceedings of a Symposium organized by the Royal College of Physicians

#### Edited by Derrick A. Brewerton

Supplement 1. Vol. 34, 1975

Speakers and Additional Discussants

Ankylosing spondylitis and HL-A 27 D. C. G. James

Identification of HL-A antigens by serological criteria J. R. Batchelor Mixed lymphocyte reaction stimulating antigens, their detection and relation to diseases, and other markers of the major histocompatibility system H. Festenstein and J. Pena-Martinez

The HL-A system and its association with immune response and disease W. F. Bodmer

Disease predisposition, immune responsiveness, and the fine structure of the HL-A supergene. A need for reappraisals J. J. van Rood, J. P. van Hooff and J. J. Keuning

Family studies indicating genetic factors in rheumatic disease V. Wright Reiter's disease and HL-A 27 A. Nicholls

HL-A 27 in reactive arthritis following infection K. Aho, P. Ahvonen, P. Alkio, A. Lassus, E. Sairanen, K. Sievers, and A. Tiilikainen

HL-A 27 and the spondylitis of chronic inflammatory bowel disease and psoriasis R. Bluestone, R. I. Morris, A. L. Metzger and P. I. Terasaki HL-A 27 and acute anterior uveitis D. A. Brewerton

HL-A antigens in juvenile chronic polyarthritis (Still's disease) A. Hall, B. M. Ansell, D. C. O. James and P. Zylinski

Family studies on ankylosing spondylitis R. D. Sturrock, H. M. Dick, N. Henderson and W. C. Dick

Family studies J. C. Woodrow

Aberrant immunity in W27-positive rheumatic disease R. Bluestone, L. S. Goldberg, R. H. Weisbart, R. I. Morris and E. J. Holborow

Lymphocyte function in ankylosing spondylitis B. Nikbin, D. A. Brewerton, N. Byrom, D. C. O. James, S. Malka, L. McLeod, L. Slater, R. E. Warren and J. R. Hobbs

**Brief Clinical Reports** 

HL-A 27 and ankylosing spondylitis. A family study J. M. J. P. van der Linden, A. Cats, J. J. Keuning, J. J. van Rood, and J. H. C. Wuisman Behçet's disease M. A. Chamberlain Circinate erosive balanitis K. Aho
Panel Discussion

Concluding Remarks A. C. Allison

#### Price £2.50 (U.S.A. \$7.50) including postage

#### This publication can be ordered now from

The Publishing Manager, ANNALS OF THE RHEUMATIC DISEASES, B.M.A. House, Tavistock Square, London WC1H 9JR

International Journal of Gastroenterology

#### Contents Vol. 11, No. 3-4, 1974

Fölsch, U.R.; Winckler, K., and Wormsley, K.G. (Göttingen/Dundee): Effect of a Soybean Diet on Enzyme Content and Ultrastructure of the Rat Exocrine Pancreas	161
Tiscornia, O.; Palasciano, G., and Sarles, H. (Marseille): Effects of Chronic Ethanol Administration on Canine Exocrine Pancreatic Secretion. Further Studies	172
Jordö, L.; Olsson, R., and Scherstén, T. (Göteborg): Effects of Long-Term Administration of Different Alcoholic Beverages to Rats on Liver Lipid Metabolism and Bile Acid Conjugation	183
Rommel, K. and Böhmer, R. (Ulm): Influence of Secretin and Cholecystokinin on Maltase, Sucrase and Lactase in the Jejunum of the Rat	194
Robert, A.; Nezamis, J.E.; Lancaster, C., and Badalamenti, J.N. (Kalamazoo, Mich.): Cysteamine-Induced Duodenal Ulcers: A New Model to Test Antiulcer Agents	199
Vagne, M. and Perret, G. (Lyon): Interaction of Secretin and Carbaminolchoy- line on Gastric Secretion in Cats	215
Moore, J.G. and Wolfe, M. (Salt Lake City, Utah): Circadian Plasma Gastrin Patterns in Feeding and Fasting Man	226
Mazzacca, G.; Budillon, G.; De Marco, F., and De Ritis, F. (Naples): Serum Gastrin in Patients with Cirrhosis of the Liver	232
Morishita, R.; Fujii, M.; Yamamoto, T.; Wakisaka, G.; Matsumoto, Y., and Ono, H. (Kyoto): Effect of Pancreatin on Vitamin B <sub>12</sub> Malabsorption in Patients with Total Pancreatectomy	240
Nagaratnam, N.; Silva, D.P.K.M. de, and Silva, S.P. de: Active Chronic Hepatitis in Sri Lanka Patients	249
Resnick, R.H.; Boitnott, J.; Iber, F.L.; Makopour, H., and Cerda, J.J. (Boston, Mass./Baltimore, Md./Gainesville, Fla.): Preliminary Observations of d-Penicillamine Therapy in Acute Alcoholic Liver Disease	257
Pansu, D.; Berard, A.; Dechelette, M.A., and Lambert, R. (Lyon): Influence of Secretin and Pentagstrin on the Circadian Rhythm of Cell Proliferation in the Intestinal Mucosa in Rats	266
Johnston, D. (Leeds): Physiological and Clinical Significance of Highly Selective Vagotomy without a Drainage Procedure	275



Basel München Paris London New York · Sydney

Please enter my subscription

275

Please send me a specimen copy

Address .